Back to List View Graph View

Chimeric Antigen Receptor T-cell therapy

Chimeric antigen receptor T-cell therapy is an adoptive cellular immunotherapy in which a patient’s T cells are collected, commonly by leukapheresis, and genetically modified to express a chimeric antigen receptor (CAR).

Where the papers sit

8 papers from the last 6 months study Chimeric Antigen Receptor T-cell therapy directly · updated from PubMed 16 Nov 2026

  • Relapsed Myeloma Treatment

    CAR T-cell therapy and bispecific antibodies are being weighed as single or sequential treatments for relapsed/refractory multiple myeloma. Progression and therapeutic response remain central, with the optimal order and patient selection unresolved. Central nervous system involvement adds a high-risk clinical course that may complicate treatment choice. Economic work is also moving toward AI-supported, hospital-based CAR T production as a way to improve access and cost-effectiveness.

    4 papers · 50%

  • CAR-T Safety and Outcomes

    CAR-T outcome research is widening from remission to cardiovascular, neurologic, and cognitive safety. Cytokine release syndrome and neurotoxicity remain recurring concerns, while Montreal Cognitive Assessment results address medium-term function after treatment for CNS lymphoma. Medicare data quantify cardiovascular outcomes at population scale. The ENCIT01 trial tests whether third-generation L1CAM-specific CAR T cells improve on second-generation cells in primary refractory CNS lymphoma.

    3 papers · 37.5%

  • CAR-T for Immune Thrombocytopenia

    BCMA-directed CAR T-cell therapy is being tested as a way to reset refractory primary immune thrombocytopenia. The reported pattern combines platelet recovery with durable drug-free remission, rather than continuing immune-directed medication. Thrombocytopenia and immune thrombocytopenia define the clinical endpoint, with B-cell Maturation Antigen providing the target. Durability, safety, and reproducibility beyond this early evidence remain open questions.

    1 papers · 12.5%

Papers

The 8 papers from the last 6 months that study Chimeric Antigen Receptor T-cell therapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Relapsed Myeloma Treatment (4)
  1. Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. JMIR cancer · 13 Oct 2026 PMID 42868529
  2. Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma. Blood cancer discovery · 13 Aug 2026 PMID 42593166
  3. Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement. Blood advances · 25 Jun 2026 PMID 42348786
  4. Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. Blood cancer discovery · 12 Jun 2026 PMID 42284467
CAR-T Safety and Outcomes (3)
  1. Medium-Term Cognitive Outcome in Patients With CNS Lymphomas Treated With Chimeric Antigen Receptor T-Cell Therapy. Neurology · 2 Oct 2026 PMID 42826379
  2. The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 18 Jun 2026 PMID 42312971
  3. Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries. European heart journal · 27 May 2026 PMID 42199067
CAR-T for Immune Thrombocytopenia (1)
  1. BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia. Blood · 24 Jul 2026 PMID 42498681

By study type

Clinical trials (1)
  1. The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 18 Jun 2026 PMID 42312971
Observational studies and case reports (4)
  1. Medium-Term Cognitive Outcome in Patients With CNS Lymphomas Treated With Chimeric Antigen Receptor T-Cell Therapy. Neurology · 2 Oct 2026 PMID 42826379
  2. Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement. Blood advances · 25 Jun 2026 PMID 42348786
  3. Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. Blood cancer discovery · 12 Jun 2026 PMID 42284467
  4. Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries. European heart journal · 27 May 2026 PMID 42199067
Human data, design not indexed (3)
  1. Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. JMIR cancer · 13 Oct 2026 PMID 42868529
  2. Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma. Blood cancer discovery · 13 Aug 2026 PMID 42593166
  3. BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia. Blood · 24 Jul 2026 PMID 42498681